Orphan drug designation application submitted by jaguar health subsidiary for crofelemer for short bowel syndrome with intestinal failure accepted for review by european medicines agency

The conditional marketing authorization pathway in europe for crofelemer for this orphan disease is the initial focus of napo eu under the license agreement between napo eu and napo pharmaceuticals jaguar to host investor webcast monday, september 20th at 8:30 a.m. eastern; click here to register for webcast san francisco, ca / accesswire / september 15, 2021 / jaguar health (nasdaq:jagx) today announced that the european medicines agency (ema) has confirmed that the orphan drug designation (odd) application for crofelemer submitted by napo eu s.p.a.
JAGX Ratings Summary
JAGX Quant Ranking